FAQ on Clene's Upcoming FDA Meeting to Discuss CNM-Au8® Biomarker for ALS

What is the main topic of Clene’s upcoming meeting with the FDA?

The main topic is to discuss Clene’s CNM-Au8® biomarker and related clinical and survival data for amyotrophic lateral sclerosis (ALS).

Why is this meeting significant?

This meeting is significant because it involves discussions with FDA leadership and key opinion leaders on ALS biomarkers and clinical endpoints, which are crucial for understanding and advancing CNM-Au8® as a treatment for ALS.

Who will attend the meeting from the FDA?

Attendees will include the FDA’s Director of the Office on New Drugs, the Director of the Office of Neuroscience, and the Division of Neurology 1 (‘DN1’) review team, along with recognized key opinion leaders in ALS, biostatistics, and biomarkers.

What is CNM-Au8®?

CNM-Au8® is an investigational first-in-class therapy by Clene that aims to improve central nervous system cells’ survival and function by targeting mitochondrial function and the NAD pathway while reducing oxidative stress.

Where can I find more information about Clene and its research?

For more information, please visit www.Clene.com.

What diseases is Clene focusing on treating?

Clene is focused on treating neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

How does Clene view the FDA’s role in this process?

Clene appreciates the FDA’s use of process and regulatory flexibility to obtain the best outcome for people living with ALS.

Where is Clene based?

Clene is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland.

Where can I view the full article about this meeting?

The full article can be viewed at https://ibn.fm/3O2Zt.

Who should I contact for more information about Clene’s investor relations?

For more information, you can contact IBN (InvestorBrandNetwork) at Editor@InvestorBrandNetwork.com or visit https://www.InvestorBrandNetwork.com.